reiter op rel weak stori
unchang refresh model
view left week ralli versu
neg headlin stori unchang see
overli materi impact refresh model ad
conservat upjohn deal expect close due
see meaning upsid side close
reiter op rate target model updat
viatri stori look past near-
term think manag new
pro-forma ebitda modestli lower billion billion
exhibit made sever chang stand-alone model
includ temper revenu gross margin off-set
lower spend leav us conserv lower end
guidanc rang upcom said
believ compani seen materi impact busi
point admittedli visibl midst low
updat upjohn forecast conjunct model revisit
also assum basi point higher interest rate blend billion
new issu debt upon close bridg loan financ
day loan start acquisit close provid plenti
time ride credit volatil ie later close date could help
remain best way play sector recoveri view
chang stori re-rat potenti last two day
spoke includ chairman robert couri
much stock weak like relat india lock-down
epipen auto-injector error headlin link stori chang
end close viatri re-domicil delawar
ii add three high profil director board iii pay dividend
yield iv leverag target new ceo/
cfo
mean valuat outlook look
newco viatri pro-forma valuat
ev/ebitda price-to-earnings beyond broader impact think
market price uncertainti around two thing risk pro-forma
ebitda expect volatil share suppli holder
set receiv newco could return market latter
remain question close ebitda risk
report pharmaceut stock stock stress test analysi underscor
lc pharma safeti risk highli lever gener tri look
cut profroma ebitda billion assum
cost off-set impli valuat would ev/ebitda price-to-earnings
valu usd unless otherwis note
dissemin produc price prior trade day market close estimate unless otherwis note
bloomberg capit market estim upside/downside/target
base case scenario see stock price impli
price-to-earnings ep
announc combin pfe upjohn off-
patent busi grow diversifi myl revenu
base beyond us gener term agreement
holder combin entiti newco
domicil us govern delawar law
invest thesi larg unchang pre-
announc one diversifi generic/
biosimilar pipelin industri believ help
withstand impact moreov optimist
newco deliv posit chang corpor
govern perspect follow primari driver
outperform thesi stock
face mani sector headwind
pressur peer given diversif activ
reposit think see growth improv
come year
sever import pipelin catalyst
drive support improv sentiment
myl/upjohn newco trade combin ebitda
long-term growth outlook appear stabl increasingli
full synergi captur
steadi new gener approv activ high-single-digit
us gener eros base busi
continu ramp recent new product launch
gener copaxon fulphila gener advair
plan combin pfe upjohn busi
add diversif creat signific
oper effici greater scale target
least billion annual cost synergi
risk view delay around pipelin convers and/
lower-than-expect uptak new launch
impair us base busi risk anoth step-
ebitda contribut delay upjohn deal close
and/or integr issu prevent newco hit
financi target inopportun use cash boost
leverag and/or impair sharehold valu greater
impact model
upcom potenti catalyst event focu
deal close pfe upjohn busi expect
launch progress major new launch gener
copaxon fulphila wixela addit accret use
capit debt pay-down
upsid scenario see valu impli price-to-earnings
ep
myl/upjohn newco trade combin ebitda
higher expect synergi captur
inflect higher gener approv activ continu
limit competit high-valu gener greater-
downsid scenario see valu impli price-to-earnings
ep
myl/upjohn trade combin ebitda
greater competit pressur across us gener
portfolio lead lower expect new launch uptak
slowdown ou fail off-set pressur us
greater impact anticip
exhibit pro-forma newco ebitda still billion rang post-synergi
forma current adj ebitda net ep upjohn pro forma revenu upjohn guidanc ebitda margin per guid combin pro forma revenu trough year add cost synergies- per year reach least billion total combin pro-forma adj ebitda forma ebitda margin depreci actual upjohn estimateless legaci lless newco assum cost newco debt annual de-leverpre-tax incom assum tax re-domicil us current ratesassum tax net incom share count impli base pro forma ownershipnewco forma assumptionscom share march close share current share outstand market cap pre-deal close newco deal specif newco share impli share count base state post deal ownershipimpli equiti valu equiti valu pre-deal valuat levelimpli equiti valu impli equiti valu price target impli ev/ebitda pro-forma forecast impli equiti valu equiti valu equiti valu structurecom net debt end use end reflect one year cash gener new debt total newco net debt target total debt close consist paydown cf forma capit end target gross leverag end
exhibit stand-alone
 incom guid lsd growth north guid mid high singl digit growth eurest guid msd growth rowoth gener total revenu guid billion lowest qcost gross profit incom incom incom tax incom guid incom prefer dividend adjust net ep adjust dilut share guid million guid billion year growth ebitda analysi margin expens guid net incom pharmaceuticals/specialti
price target base equal price-to-earnings ev/ebitda multipl appli newco
estim use target multipl respect result
gener price target framework taken trough price-to-earnings valuat
histor averag ev/ebitda valuat made adjust base company-specif
attribut ev/ebitda incorpor opioid liabil within capit structur
price target modestli valuat level trade pre-deal announc
sector histor averag multipl reflect continu challeng
industri impli return price target opportun upsid support
risk rate price target
risk rate price target includ limit delay around pipelin
convers slower expect new launch uptak impair us
base busi delay upjohn deal close and/or integr issu inopportun
use cash boost leverag and/or impair sharehold valu
lead global gener manufactur base pittsburgh pennsylvania employ
approxim peopl global compani found transform
last sever year notabl acquisit merck kgaa
compani benefit differ revenu sourc help grow
eu auster headwind us comp strength recent year
